
Ovarian Cancer Drug Begins Phase III Trials
IMUNON, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, announced that the first trial site has been initiated for the Company’s Phase 3 pivotal study, called OVATION 3, of its lead candidate IMNN-001 in development for …